Oncofetal antigen/immature laminin receptor protein in pregnancy and cancer

• Autorzy: Barsoum A.L. , Schwarzenberger P. O.
• Języki publikacji: EN

Abstrakty

EN

The 37-kDa immature laminin receptor protein (iLRP) is a speciesconserved, universal immunogenic protein that is expressed in all thus-far examined embryonic and early fetal cells of inbred and outbred rodents. It has also been identified in human concepti. It is altered through normal maturation processes to become a non-immunogenic 67-kDa dimeric mature laminin receptor protein (mLRP) in mid-to late gestation in the mammalian fetus. This antigen ceases to be expressed as an active autoimmunogen in the full-term fetus and in the normal differentiating tissues and organs of the neonate or adult organism, apparently due to dimerization, but it is re-expressed as an immunogenic monomer in tumor cells. In this review, we highlight the known mechanisms of immune responses with particular emphasis on the possible role of the 37-kDa oncofetal antigen/immature laminin receptor (OFA/iLRP) in both pregnancy and cancer.

Słowa kluczowe

EN

oncofetal antigen; immature laminin receptor; protein; pregnancy; cancer; laminin receptor; immune response

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2014
• Tom: 19
• Numer: 3
• Opis fizyczny: p.393-406,fig.,ref.

Twórcy

autor

Barsoum A.L.

• Department of Microbiology and Immunology, University of South Alabama, Mobile, AL 36688, USA
• Quantum Immunologics, Mobile, AL 36688, USA

autor

Schwarzenberger P. O.

• Department of Microbiology and Immunology, University of South Alabama, Mobile, AL 36688, USA
• Quantum Immunologics, Mobile, AL 36688, USA

Bibliografia

• 1.Billingham, R.E., Brent, L. and Medawar, P.B. ‘Actively acquired tolerance’ of foreign cells. 1953. J. Immunol. 184 (2010) 5–8.
• 2. Billington, W.D. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J. Reprod. Immunol. 60 (2003) 1–11.
• 3. Smith, T.R. and Kumar, V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 29 (2008) 337–342. DOI: 10.1016/j.it.2008.04.002.
• 4. Saito, S., Shiozaki, A., Sasaki, Y., Nakashima, A., Shima, T. and Ito, M. Regulatory T cells and regulatory natural killer (NK) cells play important roles in feto-maternal tolerance. Semin. Immunopathol. 29 (2007) 115– 122. DOI: 10.1007/s00281-007-0067-2.
• 5. Wegmann, T.G, Lin, H., Guilbert, L. and Mosmann, T.R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today 14 (1993) 353–356.
• 6. Liu, F., Guo, J., Tian, T., Wang, H., Dong, F., Huang, H. and Dong, M. Placental trophoblasts shifted Th1/Th2 balance toward Th2 and inhibited Th17 immunity at fetomaternal interface. APMIS 119 (2011) 597–604. DOI: 10.1111/j.1600-0463. 2011. 02774.x.
• 7. Van Mourik, M.S., Macklon, N.S. and Heijnen, C.J. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J. Leukoc. Biol. 85 (2009) 4–19.
• 8. Knutson, K.L. and Disis, M.L. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54 (2005) 721–728.
• 9. Blois, S.M., Kammerer, U., Alba Soto, C., Tometten, M.C., Shaikly, V., Barrientos, G., Jurd, R., Rukavina, D., Thomson, A.W., Klapp, B.F., Fernandez, N. and Arck, P.C. Dendritic cells: key to fetal tolerance? Biol. Reprod. 77 (2007) 590–598. DOI: 10.1095/biolreprod.107.060632.
• 10. Geissmann, F., Manz, M.G., Jung, S., Sieweke, M.H., Merad, M. and Ley, K. Development of monocytes, macrophages, and dendritic cells. Science 327 (2010) 656–661.
• 11. Nelson, D. and Ganss, R. Tumor growth or regression: powered by inflammation. J. Leukoc. Biol. 80 (2006) 685–690.
• 12. Zamarron, B. F. and Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7 (2011) 651–658.
• 13. Steinman, R.M., Hawiger, D. and Nussenzweig, M.C. Tolerogenic dendritic cells. Annu Rev. Immunol. 21 (2003) 685–711.
• 14. Walker, M.R., Kasprowicz, D.J., Gersuk, V.H., Benard, A., Van Landeghen, M., Buckner, J.H. and Ziegler, S.F. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112 (2003) 1437–1443.
• 15. Aluvihare, V.R., Kallikourdis, M. and Betz, A.G. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5 (2004) 266–271. DOI: 10.1038/ni1037.
• 16. Zhao, J.X., Zeng, Y.Y. and Liu, Y. Fetal alloantigen is responsible for the expansion of the CD4(+)CD25(+) regulatory T-cell pool during pregnancy. J. Reprod. Immunol. 75 (2007) 71–81. DOI: 10.1016/j.jri.2007.06.05217.
• 17. Blois, S.M., Joachim, R., Kandil, J., Margni, R., Tometten, M., Klapp, B.F. and Arck, P.C. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J. Immunol. 172 (2004) 5893–5899.
• 18. Wang, H.Y. and Wang, R.F. Regulatory T cells and cancer. Curr. Opin. Immunol. 19 (2007) 217–223.
• 19. Rohrer, J.W. and Coggin, J.H., Jr. CD8 T-cell clones inhibit antitumor T-cell function by secreting IL-10. J. Immunol. 155 (1995) 5719–5727.
• 20. Rohrer, J.W., Culpepper, C., Barsoum A.L. and Coggin, J.H., Jr. Characterization of RFM mouse T lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T lymphocyte cloning. J. Immunol. 154 (1995) 2266–2280.
• 21. Rabinovich, G.A., Baum, L.G., Tinari, N., Paganelli, R., Natoli, C., Liu, F.T. and Iacobelli, S. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol. 23 (2002) 313–220.
• 22. Cooper, D., Ilarregui, J.M., Pesoa, S,A., Croci, D.O., Perretti, M. and Rabinovich, G.A. Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol. 480 (2010) 199–244. DOI: 10.1016/s0076-6879(10)80011-423.
• 23. Peng, W., Wang, H.Y., Miyahara, Y., Peng, G. and Wang, R.F. Tumorassociated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res. 68 (2008) 7228–7236. DOI: 10.1158/0008-5472.can-08- 124524.
• 24. Coggin, J.H. Jr., Barsoum, A.L. and Rohrer, J.W. 37-kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res. 19 (1999) 5535–5542.
• 25. Barsoum, A.L., Rohrer, J.W., Coggin, J.H., Jr. 37kDa Oncofetal antigen is an autoimmunogenic homologue of the 37kDa laminin receptor precursor. Cell. Mol. Biol. Lett. 5 (2000) 207–230.
• 26 Castronovo, V. Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 13 (1993) 1–30.
• 27 Castronovo, V., Claysmith, A.P., Barker, K.T., Cioce, V., Krutzsch, H.C. and Sobel, M.E. Biosynthesis of the 67 kDa high affinity laminin receptor. Biochem. Biophys. Res. Commun. 177 (1991) 177–183.
• 28 Castronovo, V., Taraboletti, G. and Sobel, M.E. Functional domains of the 67-kDa laminin receptor precursor. J. Biol. Chem. 266 (1991) 20440–20446.
• 29. Coggin, J.H., Jr., Adkinson, L. and Anderson, N.G. Fetal antigens shared as transplantation rejection antigens on chemically induced mouse and hamster sarcomas. Cancer Res. 40 (1980) 1568–1573.
• 30. Rohrer, J.W., Rohrer, S.D., Barsoum, A. and Coggin, J.H., Jr. Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor transplantation antigens by syngeneic cloned BALB/c and RFM mouse T cells. J. Immunol. 152 (1994) 754–764.
• 31. Rohrer, J.W., Barsoum, A.L., Dyess, D.L., Tucker, J.A. and Coggin, J.H., Jr. Human breast carcinoma patients develop clonable oncofetal antigenspecific effector and regulatory T lymphocytes. J. Immunol. 162 (1999) 6880–6892.
• 32. Holtl, L., Zelle-Rieser, C., Gander, H., Papesh, C., Ramoner, R., Bartsch, G., Rogatsch, H., Barsoum, A.L., Coggin, J.H., Jr. and Thurnher, M. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. 8 (2002) 3369–3376.
• 33. Friedrichs, B., Siegel, S., Kloess, M., Barsoum, A., Coggin, J., Jr., Rohrer, J., Jakob, I., Tiemann, M., Heidorn, K., Schulte, C., Kabelitz, D., Steinmann, J., Schmitz, N. and Zeis, M. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. J. Immunol. 180 (2008) 6374–6384.
• 34. Payne, W.J., Jr. and Coggin, J.H., Jr. Mouse monoclonal antibody to embryonic antigen: development, cross- reactivity with rodent and human tumors, and preliminary polypeptide characterization. J. Nat. Cancer Inst. 75 (1985) 527–544.
• 35. Coggin, J.H., Jr. and Anderson, N.G. Cancer, differentiation and embryonic antigens: some central problems. Adv. Cancer Res. 19 (1974) 105–165.
• 36. Coggin, J.H., Jr., Rohrer, S.D., Hester, R.D., Barsoum, A.L., Rashid, H.U. and Gussack, G.S. 44-kd oncofetal transplantation antigen in rodent and human fetal cells. Implications of recrudescence in human and rodent cancers. Arch. Otolaryngol. Head Neck Surg. 119 (1993) 1257–1266.
• 37. Coggin, J.H., Jr. Embryonic antigens in malignancy and pregnancy: common denominators in immune regulation. Ciba Found. Symp. 96 (1983) 28–54.
• 38. Zhang, C., Duan, E., Cao, Y., Jiang, G. and Zeng, G. Effect of 32/67 kDa laminin-binding protein antibody on mouse embryo implantation. J. Reprod. Fertil. 119 (2000) 137–142.
• 39. Coggin, J.H., Jr. The implications of embryonic gene expression in neoplasia. Crit. Rev. Oncol. Hematol. 5 (1986) 37–55.
• 40. Chakravarty, P.K. and Sinha, D.K. Pregnancy induced mammary tumor specific effector cells are present long after parturition in a breast cancer model in rats. Cancer Letts. 154 (2000) 1–7.
• 41. Janerich, D.T. The fetal antigen hypothesis: cancers and beyond. Medical Hypotheses 56 (2001) 101–103. DOI: 10.1054/mehy.2000.1119.
• 42. Rohrer, S.D, Sarli, R.N., Barsoum, A.L, Hester, R.B. and Coggin, J.H., Jr. Expression of 44-kilodalton oncofetal antigen as a premalignancy marker in X irradiation-induced murine T-cell lymphoma. J. Nat. Cancer Inst. 84 (1992) 602–609.
• 43. Menard, S., Castronovo, V., Tagliabue, E. and Sobel, M.E. New insights into the metastasis-associated 67 kD laminin receptor. J. Cell. Biochem. 67 (1997) 155–165.
• 44 Gussack, G.S., Rohrer, S.D., Hester, R.B., Liu, P.I. and Coggin, J.H., Jr. Human squamous cell carcinoma lines express oncofetal 44-kD polypeptide defined by monoclonal antibody to mouse fetus. Cancer 62 (1988) 283–290.
• 45. Zelle-Rieser, C., Barsoum, A.L., Sallusto, F., Ramoner, R., Rohrer, J.W., Holtl, L., Bartsch, G., Coggin, J.H., Jr. and Thurnher, M. Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma. J. Urol. 165 (2001) 1705–1709.
• 46. Siegel, S., Wagner, A., Kabelitz, D., Marget, M., Coggin, J., Jr., Barsoum, A., Rohrer, J., Schmitz, N. and Zeis, M. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102 (2003) 4416–4423. DOI: 10.1182/blood-2003-01-0198.
• 47. Siegel, S., Wagner, A., Friedrichs, B., Wendeler, A., Wendel, L., Kabelitz, D., Steinmann, J., Barsoum, A., Coggin, J., Rohrer, J., Dreger, P., Schmitz, N. and Zeis, M. Identification of HLA- A*0201-presented T-cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J. Immunol. 176 (2006) 6935–6944.
• 48. Friedrichs, B., Siegel, S., Reimer, R., Barsoum, A., Coggin J., Jr., Kabelitz D., Heidorn, K., Schulte, C., Schmitz, N. and Zeis, M. High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. Leuk. Res. 35 (2011) 721–729. DOI: 10.1016/j.leukres.2010.10.002.
• 49. Rohrer, J.W., Barsoum, A.L. and Coggin, J.H., Jr. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T-cell clones. J. Immunol. 176 (2006) 2844–2856.
• 50. Barsoum, A.L., Liu, B., Rohrer, J.W., Coggin, J.H., Jr., Tucker, J.A., Pannell, L.K. and Schwarzenberger, P.O. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein. Biomaterials 30 (2009) 3091–3099. DOI: 10.1016/j.biomaterials.2009.02.022.
• 51. Coggin, J.H., Jr., Barsoum, A.L. and Rohrer, J.W. Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol. Today 19 (1998) 405–408.
• 52. Buto, S., Tagliabue, E., Ardini, E., Magnifico, A., Ghirelli, C., van den Brule, F., Castronovo, V., Colnaghi, M.I. and Sobel, M.E. Formation of the 67-kDa laminin receptor by acylation of the precursor. J. Cell. Biochem. 69 (1998) 244–251.
• 53. Karpatova, M., Tagliabue, E., Castronovo, V., Magnifico, A., Ardini, E., Morelli, D., Belotti, D., Colnaghi, M.I. and Menard, S. Shedding of the 67-kD laminin receptor by human cancer cells. J. Cell. Biochem. 60 (1996) 226–234.